You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (GenomeWeb) – CareFirst Blue Cross Blue Shield said today that it will cover Exosome Diagnostics' ExoDx Prostate IntelliScore (EPI) prostate cancer test based on the results of an evidence development study launched last year.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.
As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.